uk en
LIFE SCIENCES LAWYERS | UKRAINE & CIS
Menu

LA LAW FIRM (Legal Alliance) founded in 1995, is today one of the leading Ukrainian law firms that provides comprehensive corporate counselling and practical support to national and global companies in Ukraine, СEE & Central Asia.

OUR CLIENTS represent life sciences industries including healthcare and pharmaceuticals, medical devices, cosmetics, biotechnology as well as healthcare institutions.

LEADING ASSOCIATIONS — AIPM Ukraine, APRaD as well as the EBA Healthcare Committee have chosen LA Law Firm as their legal advisor.

312
LA Law Firm has once again been recognised by the prestigious international legal directory, The Legal 500, in its 2026 EMEA edition.
350
LA Law Firm has been officially recognized by Chambers Europe, one of the world’s most prestigious and rigorous legal directories.
2224
Improving access to safe and affordable medicines for the Ukrainian population is one of the Government of Ukraine's top priorities. SAFEMed Activity (2017-2025) has supported this effort by appIying health system strengthening best practices.
1683
LA Law Firm is the exclusive Ukraine contributor to the first-ever Intellectual Property Legal Landscape chapter by Legal 500. In this Comparative Guide repor
2050
LA Law Firm has improved its standing in the "Market Leaders. Ranking of Law Firms — 2025" an annual assessment by the editorial board of Yuridychna Gazeta.
1623
Medical Procurement of Ukraine and the international pharmaceutical company Roche have entered into an investment agreement to localize the manufacturing of oncology medicines in Ukraine.
2011
LA Law Firm partner Vitalii Savchuk explains current practice trends and their implications for both business and the defense sector. — Yur-Gazeta, 25.04.2025
1935
We are delighted to announce that LA Law Firm has been shortlisted for UKRAINE Firm of the Year in the 2025 awards.
1103
LIGA.net, March 21, 2025The extension of patents for the period of martial law creates obstacles to the timely entry of new medicines into the Ukrainian market.
2228
Bolar Exemption allows generic drug manufacturers to start marketing authorization process for a medicinal product before the patent for the generic medicinal product expires.
If you find out a mistake, please, mark it and select Ctrl+Enter to inform us